Safety in pediatric sedation relies on strict guidelines and monitoring, so let's learn how providers utilize pharmacological ...
Morning Overview on MSN
A new ‘autopilot’ medical device could speed heart attack recovery
Heart attack care is entering a phase where machines do not just assist doctors, they anticipate the next move. A new ...
Next-Generation Novasight Hybrid™ System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing ...
As many as nine million Britons may be unknowingly at heightened risk of heart attacks, strokes and kidney failure because ...
Curious to know which obesity stories grabbed the attention of readers this year? Medscape Medical News develops a list of ...
Emirates News Agency on MSN
DoH, Ma’an open applications for 2026 Healthcare Research and Innovation Fund
Abu Dhabi (DoH), the regulator of the healthcare sector, in collaboration with the Authority of Social Contribution – Ma’an, ...
A nationwide survey by the Alzheimer’s Association in 2025 found close to 4 in 5 Americans 45 and older want to know if they have Alzheimer’s before symptoms appear. And 91% said they would take a ...
Next-Generation Novasight Hybrid System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption of Image-Guided PCIPeer-Reviewed Publications Highli ...
Every winter, India’s air pollution crisis returns with stark visibility. Smog blankets Delhi and much of the Indo-Gangetic Plain, flights are disrupted, schools shut, and emergency health advisories ...
Rapid global population aging is reshaping healthcare systems, with older adults accounting for an increasing share of disease burden, healthcare ...
Live Science on MSN
Scientists are developing a 'self-driving' device that helps patients recover from heart attacks
Live Science spoke with Dr. Joe Alexander of NTT Research about "digital twins" and the development of an autonomous device ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results